Cue Biopharma, Inc. 8-K

What Happened Cue Biopharma, Inc. announced in an 8-K (filed Feb 18, 2026) that its 2026 Annual Meeting of Stockholders will be held on April 13, 2026. The company stated deadlines for stockholder proposals to be included in the company’s proxy materials and for director nominations or other advance-notice items under its Amended and Restated Bylaws. The filing was signed by President and CEO Usman Azam.

Key Details

• Annual meeting date: April 13, 2026.
• Proxy inclusion deadline (Rule 14a-8): proposals received on or before February 28, 2026 will be treated as timely for inclusion in the proxy statement and proxy card.
• Bylaws advance-notice deadline for nominations/other actions: notice must be received by the later of 90 days before the meeting or 10 days after mailing/public announcement — for this meeting that deadline is February 28, 2026.
• Universal proxy (Rule 14a-19) notice deadline for stockholder proxy solicitations: also falls on February 28, 2026 for this meeting.
• If a stockholder misses the advance-notice deadline, proxies solicited by the Board may exercise discretionary voting on the matter.

Why It Matters These deadlines are important for investors who want to submit proposals or nominate directors: missing the Feb 28, 2026 deadline may prevent inclusion in the company’s proxy materials or limit a nominator’s ability to solicit proxies under the universal proxy rule. Retail investors, activist shareholders, or anyone planning to propose corporate actions or board nominees should note the dates and the filing procedures (Rule 14a-8 and 14a-19 and the company’s Bylaws) to ensure their items are considered.